MedTrace Logo

4SCAR-CD44v6 T Cell Therapy Targeting Cancer

NCT04427449 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2020-06-11

No results posted yet for this study

Summary

The purpose of this clinical trial is to assess the feasibility, safety and efficacy of 4SCAR-CD44v6 T-cell therapy targeting multiple cancers. The study also aims to learn more about the function of the CD44v6 CAR-T cells and their persistency in the patients.

Conditions

  • Cancers Which Are CD44v6 Positive

Interventions

BIOLOGICAL

CD44v6-specific CAR gene-engineered T cells

4SCAR-CD44v6 Infusion of 4SCAR-CD44v6 T cells at 10\^6 cells/kg body weight

Sponsors & Collaborators

  • Shenzhen Hospital of Southern Medical University

    collaborator OTHER

  • The Seventh Affiliated Hospital of Sun Yat-sen University

    collaborator OTHER

  • Shenzhen Children's Hospital

    collaborator OTHER_GOV

  • Shenzhen Geno-Immune Medical Institute

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
6 Months
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-06-01
Primary Completion
2023-05-31
Completion
2023-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04427449 on ClinicalTrials.gov